Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism

被引：55

作者：

Stacy Z.A. ^{[1
]}

Call W.B. ^{[2
]}

Hartmann A.P. ^{[2
]}

Peters G.L. ^{[2
]}

Richter S.K. ^{[3
]}

机构：

[1] St. Louis College of Pharmacy, Cardiology, Mercy Hospital St. Louis, St. Louis, MO

[2] St. Louis College of Pharmacy, Internal Medicine, Barnes-Jewish Hospital, St. Louis, MO

[3] St. Louis College of Pharmacy, Ambulatory Care, VA St. Louis Health Care System-John Cochran Division, St. Louis, MO

来源：

Cardiology and Therapy | 2016年 / 5卷 / 1期

关键词：

Atrial fibrillation; Direct oral anticoagulant (DOAC); Edoxaban; Factor Xa; Factor Xa inhibitor; Non-vitamin K oralanticoagulant (NOAC); Target-specific oral anticoagulant; Venous thromboembolism; Warfarin;

D O I：

10.1007/s40119-016-0058-2

中图分类号：

学科分类号：

摘要：

Historically, vitamin K antagonists have been the only class of oral anticoagulants available. Despite our experience with warfarin over the past 60 years, its use is associated with several pharmacokinetic and clinical disadvantages including unpredictable dosing, frequent monitoring, and delayed onset and offset. Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in patients requiring chronic anticoagulation. This review examines the pharmacology and clinical data of edoxaban as a therapeutic alternative. © 2016, The Author(s).

引用

页码：1 / 18

页数：17

共 43 条

[1]

Heit J.A., The epidemiology of venous thromboembolism in the community, Arterioscler Thromb Vasc Biol, 28, 3, pp. 370-372, (2008)

[2]

Fuster V., ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, Circulation, 11

[3]

Kearon C., Gent M., Hirsh J., Weitz J., Kovacs M.J., Anderson D.R., Et al., A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism, N Engl J Med, 340, 12, pp. 901-907, (1999)

[4]

Hart R.G., Pearce L.A., Aguilar M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 12, pp. 857-867, (2007)

[5]

Beyth R.J., Quinn L.M., Landefeld C.S., Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, Am J Med, 105, 2, pp. 91-99, (1998)

[6]

The Stoke Prevention in Atrial Fibrillation Investigators, Bleeding during antithrombotic therapy in patients with atrial fibrillation, Arch Intern Med, 156, pp. 409-416, (1996)

[7]

Boehringer Ingelheim Pharmaceuticals, Inc, (2015)

[8]

Janssen Pharmaceuticals, Inc, (2015)

[9]

Bristol-Myers Squibb Company and New York, NY: Pfizer Inc, (2015)

[10]

Daiichi Sankyo, Inc, (2015)

← 1 2 3 4 5 →